Bristol Myers Squibb (BMY) Gross Profit (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Gross Profit for 18 consecutive years, with $9.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Profit rose 3.93% year-over-year to $9.2 billion in Q2 2026; TTM through Jun 2026 was $34.5 billion, a 2.91% increase from a year earlier, with the FY2025 full-year figure at $34.3 billion, changed 0.22% from the prior year.
• Gross Profit was $9.2 billion for Q2 2026 at Bristol Myers Squibb, up from $8.1 billion in the prior quarter.
• Over five years, Gross Profit peaked at $9.2 billion in Q2 2026 and troughed at $7.5 billion in Q4 2024.
• A 5-year average of $8.7 billion and a median of $8.8 billion in 2022 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit declined 13.77% in 2024 and increased 11.62% in 2025, its largest moves.
• Over 5 years, Gross Profit stood at $8.8 billion in 2022, then dropped by 0.92% to $8.7 billion in 2023, then decreased by 13.77% to $7.5 billion in 2024, then increased by 11.62% to $8.4 billion in 2025, then advanced by 10.02% to $9.2 billion in 2026.
• The last three Gross Profit figures came in at $9.2 billion (Q2 2026), $8.1 billion (Q1 2026), and $8.4 billion (Q4 2025), per Business Quant data.